Clinical trial • Phase III • Cardiology

Clinical trial in Atrial fibrillation | Transient ischemic attack | Ischemic stroke

Phase III trial for Atrial fibrillation | Transient ischemic attack | Ischemic stroke. 72 participants.

Overview

Trial Therapeutic Area
Cardiology
Trial Disease
Atrial fibrillation | Transient ischemic attack | Ischemic stroke
Trial Stage
Phase III

Key dates

Initial CTIS Submission Date
18-02-2026
First CTIS Authorization Date
15-04-2026

Trial design

Phase III trial across 1 site in Germany.

Target Sample Size
72

Eligibility

Recruits 72 No vulnerable populations selected (isVulnerablePopulationSelected=false); participants are healthy volunteers; no information on consent or assent provided..

Vulnerable Population
No vulnerable populations selected (isVulnerablePopulationSelected=false); participants are healthy volunteers; no information on consent or assent provided.

Recruitment

Planned Sample Size
72
Recruitment Window Months
9

Geography

Total Number Of Sites
1
Total Number Of Participants
72

Germany

Earliest CTIS Part Ii Submission Date
02-04-2026
Latest Decision Or Authorization Date
15-04-2026
Processing Time Days
13
Number Of Sites
1
Number Of Participants
72

Sites

Site Name
CRS Clinical Research Services Berlin GmbH
Department Name
Patient Visits
Contact Person Name
Mares-Elaine Strempler

Sponsor

Primary sponsor

Full Name
Bayer AG
Organisation Type
Pharmaceutical company
Country Of Registered Address
Germany

Contract research organisations

Name
CRS Clinical Research Services Berlin GmbH
Responsibilities
Site organisation/contact for Patient Visits (listed as site organisation and contact)

Investigational products

Combination Treatment
Yes

Related trials

Other published trials that may interest you.